On the other hand, Kropáčková et al. [28], based on the results of their study, suggested that increased serum concentrations of clusterin in treatment-naïve patients with early rheumatoid arthritis may serve as a predictive biomarker of disease activity and treatment response, which is very promising from the patients’ point of view and is worth further study for confirmation or exclusion of this observation. This evidence concerns the gene CLU and rheumatoid arthritis.